These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 12852255)

  • 21. Peroxisome proliferator-activated receptors in the cardiovascular system.
    Bishop-Bailey D
    Br J Pharmacol; 2000 Mar; 129(5):823-34. PubMed ID: 10696077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis.
    Neve BP; Fruchart JC; Staels B
    Biochem Pharmacol; 2000 Oct; 60(8):1245-50. PubMed ID: 11007963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peroxisome proliferator-activated receptors in endothelial cell biology.
    Plutzky J
    Curr Opin Lipidol; 2001 Oct; 12(5):511-8. PubMed ID: 11561170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of PPAR in cardiovascular diseases.
    Das SK; Chakrabarti R
    Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):193-209. PubMed ID: 18221086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice.
    Memon RA; Tecott LH; Nonogaki K; Beigneux A; Moser AH; Grunfeld C; Feingold KR
    Endocrinology; 2000 Nov; 141(11):4021-31. PubMed ID: 11089532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay.
    Krey G; Braissant O; L'Horset F; Kalkhoven E; Perroud M; Parker MG; Wahli W
    Mol Endocrinol; 1997 Jun; 11(6):779-91. PubMed ID: 9171241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension.
    Schiffrin EL; Amiri F; Benkirane K; Iglarz M; Diep QN
    Hypertension; 2003 Oct; 42(4):664-8. PubMed ID: 12874098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases.
    Takano H; Hasegawa H; Zou Y; Komuro I
    Curr Pharm Des; 2004; 10(22):2779-86. PubMed ID: 15320743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
    Panunti B; Fonseca V
    Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PPAR: a mediator of peroxisome proliferator action.
    Green S
    Mutat Res; 1995 Dec; 333(1-2):101-9. PubMed ID: 8538617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor gamma.
    Itoh H; Doi K; Tanaka T; Fukunaga Y; Hosoda K; Inoue G; Nishimura H; Yoshimasa Y; Yamori Y; Nakao K
    Clin Exp Pharmacol Physiol; 1999 Jul; 26(7):558-60. PubMed ID: 10405788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PPAR alpha, fibrates, lipid metabolism and inflammation.
    Duval C; Fruchart JC; Staels B
    Arch Mal Coeur Vaiss; 2004 Jun; 97(6):665-72. PubMed ID: 15283041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peroxisome proliferator-activated receptor ligands as antiatherogenic agents: panacea or another Pandora's box?
    Molavi B; Rasouli N; Mehta JL
    J Cardiovasc Pharmacol Ther; 2002 Jan; 7(1):1-8. PubMed ID: 12000972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PPARs: transcription factors controlling lipid and lipoprotein metabolism.
    Bocher V; Pineda-Torra I; Fruchart JC; Staels B
    Ann N Y Acad Sci; 2002 Jun; 967():7-18. PubMed ID: 12079830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peroxisome proliferator-activated receptors: are they involved in atherosclerosis progression?
    Puddu P; Puddu GM; Muscari A
    Int J Cardiol; 2003 Aug; 90(2-3):133-40. PubMed ID: 12957742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.
    Verreth W; De Keyzer D; Pelat M; Verhamme P; Ganame J; Bielicki JK; Mertens A; Quarck R; Benhabilès N; Marguerie G; Mackness B; Mackness M; Ninio E; Herregods MC; Balligand JL; Holvoet P
    Circulation; 2004 Nov; 110(20):3259-69. PubMed ID: 15533870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes.
    Hsueh WA; Jackson S; Law RE
    Diabetes Care; 2001 Feb; 24(2):392-7. PubMed ID: 11213897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PPAR gamma: an essential role in metabolic control.
    Fajas L; Debril MB; Auwerx J
    Nutr Metab Cardiovasc Dis; 2001 Feb; 11(1):64-9. PubMed ID: 11383325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development].
    Duran-Sandoval D; Thomas AC; Bailleul B; Fruchart JC; Staels B
    Med Sci (Paris); 2003; 19(8-9):819-25. PubMed ID: 14593612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.